1. Kor /
  2. Eng

Login Join

  1. Kor /
  2. Eng

Login Join


[강민용 교수] 2019 제71차 대한비뇨의학회 정기학술대회 학술상 수상
등록일 2019/11/19
조회수 562


강민용 교수(융합의과학과/ 의과대학 비뇨의학)께서 제71차 대한비뇨의학회 정기 학술대회에서 학술상 국외논문 '임상'우수상 을 수상하였습니다.

아래 논문관련 전이신장암 국내다기관 연구를 통해, 표적치료제로 치료받은 약 1700명의 전이신장암 환자에서 조건부 생존률을 활용한 새로운 생존 예측 모델을 제시하였다는 점에서 연구 성과를 인정받았습니다



Journal of Urology.  2018 Nov;200(5):989-995.

Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.

Minyong Kang, Jae Young Park, Chang Wook Jeong, Eu Chang Hwang, Cheryn Song, Sung-Hoo Hong, Cheol Kwak, Jinsoo Chung, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Se Hoon Park, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi and Seong Il Seo






In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time.



We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time.



Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment.



Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.






강민용교수_대한비뇨의학회 학술상 수상.jpg

이전글 다음글